RPL32P7

Across TCGA pan-cancer cohorts, RPL32P7 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RPL32P7’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where RPL32P7 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL32P7 is over-expressed in tumor.

LIHC and KIRC are the cancer types where RPL32P7 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL32P7 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.097	.012	1	view →
KIRC	Male	II,III,IV	+0.037	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

RPL32P7–LIHC

Open the LIHC breakdown →